CS MEDICA A/S: Publication of annual report 2021/2022

CS MEDICA A/S (”CS MEDICA” or the ”Company”) hereby publishes its annual report for the period October 2021 – September 2022, including the auditor’s report. The report is available as an attached document to this press release and on the Company’s website (www.cs-medica.com).

 

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech combining science and nature with the purpose of creating products for a better every day. By using modern technology to research and utilize different compounds found in the cannabis plant, we create world-changing products that offer efficient, safe treatment of autoimmune and stress-related disorders. We research, develop, manufacture, commercialize and build brands to strengthen treatment options using the therapeutic value of cannabinoids and we are currently in the market with a product portfolio, featured under the trademark CANNASEN®. Covering product categories of Pain, Skin, Hair, Protect, and Night, we offer relief and treatment for Psoriasis, Arthritis, Pain, Wound, Protection (allergy and anti-virus), Hair loss, and Sleeping disorders.

Our OTC portfolio surpasses competitive products as we are selling CE-registered medical devices with cannabidiol under medical device regulations in Europe. Thereby we revolutionize both the cannabis and medical industry, bringing innovative products and technology to the market while improving people’s lives with products that make a difference.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Tags: